The Prognostic Effect of KRAS Mutations in Non-Small Cell Lung Carcinoma Revisited: A Norwegian Multicentre Study
| Autor: | Marius Lund-Iversen, Bjørn Henning Grønberg, Erna-Elise Paulsen, Elin Richardsen, Sigve Andersen, Elisabeth Fritzke Emdal, Anine Larsen Ottestad, Hong Yan Dai, Sissel Gyrid Freim Wahl, Odd Terje Brustugun, Tarje Onsøien Halvorsen, Dagny Førde, Thomas Berg, Tom Donnem |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty KRAS G12C endocrine system diseases medicine.disease_cause survival Article Internal medicine KRAS medicine Carcinoma cohort study Progression-free survival Stage (cooking) neoplasms non-small cell lung cancer RC254-282 Mutation Lung business.industry Neoplasms. Tumors. Oncology. Including cancer and carcinogens VDP::Medisinske Fag: 700::Basale medisinske odontologiske og veterinærmedisinske fag: 710 medicine.disease VDP::Medical disciplines: 700::Basic medical dental and veterinary science disciplines: 710 digestive system diseases respiratory tract diseases medicine.anatomical_structure signalling pathway Non small cell business Kras mutation |
| Zdroj: | Cancers, Vol 13, Iss 4294, p 4294 (2021) Cancers Volume 13 Issue 17 |
| ISSN: | 2072-6694 |
| Popis: | Background: due to emerging therapeutics targeting KRAS G12C and previous reports with conflicting results regarding the prognostic impact of KRAS and KRAS G12C in non-small cell lung cancer (NSCLC), we aimed to investigate the frequency of KRAS mutations and their associations with clinical characteristics and outcome. Since mutation subtypes have different preferences for downstream pathways, we also aimed to investigate whether there were differences in outcome according to mutation preference for the Raf, PI3K/Akt, or RalGDS/Ral pathways. Methods: retrospectively, clinicopathological data from 1233 stage I–IV non-squamous NSCLC patients with known KRAS status were reviewed. KRAS’ associations with clinical characteristics were analysed. Progression free survival (PFS) and overall survival (OS) were assessed for the following groups: KRAS wild type (wt) versus mutated, KRAS wt versus KRAS G12C versus KRAS non-G12C, among KRAS mutation subtypes and among mutation subtypes grouped according to preference for downstream pathways. Results: a total of 1117 patients were included 38% had KRAS mutated tumours, 17% had G12C. Among KRAS mutated, G12C was the most frequent mutation in former/current smokers (45%) and G12D in never smokers (46%). There were no significant differences in survival according to KRAS status, G12C status, among KRAS mutation subtypes or mutation preference for downstream pathways. Conclusion: KRAS status or KRAS mutation subtype did not have any significant influence on PFS or OS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|